US Pharma MarketingExclusive: Acceleron leaders and Westlake jumpstart new IPF biotech
On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for idiopathic pulmonary fibrosis. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
After success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease.
On Tuesday, Oorja Bio launched with a $30 million Series A round, all from Westlake ...
Source: Endpoints News